Avience Biomedicals IPO
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products.
IPO GMP
+₹145
+69.71% expected gain
Price Band
₹196 - ₹208
Lot Size
1200 shares
Min Investment
₹2,49,600
Listing Date
June 25, 2026
About Avience Biomedicals
Company overview, business, and key facts.
Avience Biomedicals Limited, founded in June 2024, is a prominent manufacturer, supplier, and exporter of molecular diagnostic products, testing solutions, and laboratory equipment. The firm specializes in molecular biotechnology, genomics, and in vitro diagnostics (IVD). Avience Biomedicals Limited enhanced its product range from IVD rapid test kits to an extensive line of medical devices, including biochemistry, hematology, and serology products.
Its product range includes Rapid Test Kits, Biochemistry Analyzers and Reagents, Molecular Diagnostics, Hematology Analyzers, and Medical Devices. The company’s products are distributed to Pathology Labs, Microbiology Labs, Hospitals, and Research Centers nationwide and overseas as well. Along with manufacturing, the firm also serves as a distributor and trader of medical equipment. Moreover, its manufacturing facility is located in Noida, Uttar Pradesh.
Founded
2024
Headquarters
New Delhi
Website
https://avienbio.com/
IPO Details
Subscription Status
How many times each investor category has bid for the issue.
Strengths & Risks
Strengths
- Review: Neutral
Risks
Financials
Restated summary financials for the most recent periods.
Figures are indicative and restated for presentation.
Avience Biomedicals IPO Key Numbers
Calculated by IPOLyst from the published offer-document data. These are figures, not buy or sell calls.
Revenue growth, 2025
+88.6%
88.6% a year over the period
Profit growth, 2025
+237.9%
237.9% a year over the period
Profit margin (PAT)
15.7%
EBITDA margin 25.22%
ROE / ROCE
n/a% / 24.88%
As published in the offer document
Debt to equity
0.97
Issue mix
100% fresh / 0% sale
Fresh issue goes to the company, offer for sale to selling shareholders
GMP-implied gain per lot
₹1,74,000
1200 shares on ₹2,49,600. GMP is unofficial.
What stands out
- Healthy profit margin: PAT margin was 15.7% in 2025.
- Profit grew 237.9% in 2025.
Watch-outs
- 1 use-of-proceeds item(s) have no disclosed amount.
Scenarios apply today's grey market premium figures to the upper price band. They are illustrations, not predictions. GMP is unofficial and can be wrong.
Not yet available for this IPO: GMP history (fewer than 3 data points), post-IPO share count (market cap and P/E not computable), listed peer comparison, published risk factors.
IPO Analysis SummaryAI-generated
A plain-language review of Avience Biomedicals's financials, valuation and demand, based only on the verified figures above. For information only. It does not recommend whether to apply.
Avience Biomedicals IPO Review
Analysis based on live GMP, subscription, and issue details.
As of today, Avience Biomedicals IPO is trading at a grey market premium (GMP) of +₹145 (+69.71% estimated listing gain), indicating positive market sentiment.
The IPO has been subscribed 352.97x overall — QIB: 196.77x, NII: 427.43x, Retail: 397.02x.
Avience Biomedicals IPO subscription has closed. The shares are expected to list on June 25, 2026.
The minimum investment required is ₹2,49,600 for 1200 shares (1 lot). Retail investors can apply at cut-off price for the best chance of allotment.
Key strengths include: Review: Neutral.
Disclaimer: IPO GMP is indicative and sourced from the grey market. This is not investment advice. Please consult a SEBI-registered advisor before investing.
Avience Biomedicals IPO — Frequently Asked Questions
What is Avience Biomedicals IPO GMP today?
Avience Biomedicals IPO GMP (grey market premium) today is +₹145, suggesting an estimated listing gain of +69.71%. GMP is indicative and subject to change.
What is the price band of Avience Biomedicals IPO?
The price band for Avience Biomedicals IPO is ₹196 - ₹208 with a lot size of 1200 shares. The minimum investment required is ₹2,49,600.
When is Avience Biomedicals IPO allotment date?
Avience Biomedicals IPO allotment is expected to be finalised on June 23, 2026. You can check your allotment status on the registrar's website (Skyline Financial Services Pvt. Ltd.) using your PAN number.
When will Avience Biomedicals IPO list on NSE/BSE?
Avience Biomedicals IPO is expected to list on NSE SME on June 25, 2026.
How to check Avience Biomedicals IPO allotment status?
To check Avience Biomedicals IPO allotment status, visit the registrar's website (Skyline Financial Services Pvt. Ltd.) and enter your PAN number, application number, or DP/Client ID. You can also check on the BSE IPO allotment page at https://www.bseindia.com/investors/appli_check.aspx.
Should I apply for Avience Biomedicals IPO?
Avience Biomedicals IPO is showing a strong GMP of +₹145 (+69.71%), indicating positive market sentiment for listing gains. However, GMP is informal and not a guarantee of returns. Evaluate the company's fundamentals, price band, and your own risk appetite before applying. IPOLyst is not a SEBI-registered investment advisor — please do your own research.
What is the lot size of Avience Biomedicals IPO?
The lot size for Avience Biomedicals IPO is 1200 shares per lot. The minimum investment for retail investors is ₹2,49,600. Retail investors can apply for a maximum of 13 lots or up to ₹2 lakh, whichever is lower.